Printer Friendly

VERIDIEN CORPORATION STARTS 30-DAY CLINICAL TRIALS FOR NEW CHEMICAL COLD STERILANT

            VERIDIEN CORPORATION STARTS 30-DAY CLINICAL
               TRIALS FOR NEW CHEMICAL COLD STERILANT
    SARASOTA, Fla.,  Jan. 20 /PRNewswire/ -- Veridien Corporation, a health care company with headquarters in Sarasota, Fla., announced today that it is beginning 30-day clinical tests this week for its new chemical cold sterilant.  The clinical testing will be conducted with major universities and medical institutions and their Institutional Review Boards, in accordance with the FDA's Investigational Device Exemption (IDE) regulations.
    The company recently received a letter from the FDA identifying data needed to complete its pending Premarket Notification Submission (510|k~ application) for the new cold sterilant.  The sterilant would be marketed to hospitals and physicians' and dentists' offices for sterilizing surgical and other medical instruments, including dental handpieces and burrs, if approved by FDA.
    The company's FDA application claims that the new sterilant kills spores, bacteria, viruses, and tuberculosis in minutes at room temperature.  By contrast, sterilants now on the market take from 6 to 10 hours.  The Veridien chemical cold sterilant also differentiates itself from the present market of glutaraldehyde products because it is a non-glutaraldehyde-based sterilant.
    Veridien's sterilant formulation is based upon a proprietary, biochemically-engineered technology that adds a single ingredient to its hospital-grade disinfectant.  This disinfectant is fast-acting, highly efficacious, easy to use and low in toxicity, and has already received EPA registration.  Veridien plans to market a product line that includes both the sterilant and the hospital-grade disinfectant.
    "The clinical tests beginning this week are intended to further corroborate the usefulness of our product, the efficacy of which has already been tested in the laboratory," said Robert E. Yaw II, chairman and chief executive officer of Veridien.  "We're moving quickly and hope to measure these tests in weeks, not months."
    The Veridien chemical cold sterilant and disinfectant are infection control products in a category currently being reviewed by FDA. Recently, several competitive glutaraldehyde-based products under the Sporicidin brand name were subject to a seizure order by FDA for lack of efficacy.
    Veridien, formerly Viral Control Technology, is a Delaware corporation quoted on the OTC Electronic Bulletin Board under the symbol "VERD."
    -0-        1/20/92
    /CONTACT:  Lauren Letellier of Burson-Marsteller, 212-614-5253, for Veridien Corporation/
    (VERD) CO:  Veridien Corporation ST:  Florida IN:  MTC SU: SM -- NY046 -- 1488 01/20/92 15:10 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 20, 1992
Words:378
Previous Article:DIEBOLD ANNOUNCES IMPROVED 1991 FOURTH-QUARTER AND YEAR-END RESULTS
Next Article:FLOW-RITE AND WISCONSIN PHARMACAL ANNOUNCE PATENT LITIGATION SETTLEMENT
Topics:


Related Articles
VERIDIEN CORPORATION SEEKS INVESTMENT BANKING FIRM ASSISTANCE
/C O R R E C T I O N -- VERIDIEN/
VERIDIEN SHAREHOLDERS AMEND COMPANY'S BYLAWS TO PERMIT GREATER FLEXIBILITY IN APPOINTMENT OF DIRECTORS
VERIDIEN ANNOUNCES OFFICIAL NOTICE OF PATENT ALLOWANCE FOR VIRAHOL 1
CLARK JOINS VERIDIEN CORPORATION AS SENIOR CONSULTANT TO THE CHAIRMAN
VERIDIEN EXPECTS FDA APPROVAL SOON ON HIV VIRUS-KILLING STERIHOL(TM)
VERIDIEN ACHIEVES PROFITABILITY AT CLOSE OF 1992
Minntech Receives EPA Registration to Market Minncare Sterilant as Food Grade Sanitizer
Minntech Secures Option Rights for New Dialyzer Reprocessing Sterilant.
STERIS Corporation Receives Approval To Produce STERIS 20 In Australia.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters